 PRINCETON, N.J.--BUSINESS WIRE--UroGen Pharma Ltd. Nasdaq: URGN, a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units RSUs to nine new employees in connection with their employment with UroGen. These new team members will support the ongoing commercial launch of Jelmyto mitomycin for pyelocalyceal solution, UroGens first approved produc 